Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.55 |
| ▸ | MMP2 | P08253 | 1/20 | 0.55 |
| ▸ | MMP7 | P09237 | 1/20 | 0.55 |
| ▸ | MMP9 | P14780 | 1/20 | 0.55 |
| ▸ | MMP12 | P39900 | 1/20 | 0.55 |
| ▸ | MMP13 | P45452 | 1/20 | 0.55 |
| ▸ | BACE1 | P56817 | 3/20 | 0.54 |
| ▸ | MME | P08473 | 3/20 | 0.54 |
| ▸ | ACE | P12821 | 1/20 | 0.54 |
| ▸ | CPA1 | P15085 | 1/20 | 0.54 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.54 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30122976 | 0.94 | OPRM1 (0.56) | BACE1BACE2OPRM1OPRD1 | |
| SCHEMBL10790323 | 0.92 | BACE1 (0.60) | LTA4HMMP2MMP7MMP9MMP12 | |
| SCHEMBL10617885 | 0.91 | MME (0.53) | LTA4HMMEACECPA1ACE2 | |
| SCHEMBL10617904 | 0.91 | MME (0.53) | LTA4HMMEACECPA1ACE2 | |
| SCHEMBL28860411 | 0.91 | LTA4H (0.64) | LTA4HMMP2MMP7MMP9MMP12 | |
| SCHEMBL27517670 | 0.91 | LTA4H (0.64) | LTA4HMMP2MMP7MMP9MMP12 | |
| SCHEMBL2185269 | 0.91 | LTA4H (0.64) | LTA4HMMP2MMP7MMP9MMP12 | |
| SCHEMBL29519583 | 0.91 | LTA4H (0.64) | LTA4HMMP2MMP7MMP9MMP12 | |
| SCHEMBL1864709 | 0.91 | LTA4H (0.64) | LTA4HMMP2MMP7MMP9MMP12 | |
| SCHEMBL30504227 | 0.91 | OPRM1 (0.62) | LTA4HBACE1MMEOPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000728-A1 | PEPTIDE HAVING ACE INHIBITORY ACTIVITY AND COMPOSITION CONTAINING THE SAME | VEDAN INTERNATIONAL HOLDINGS LTD (KY) | 2026-01-01 | — | — | US | claimed |
| US-20260000728-A1 | PEPTIDE HAVING ACE INHIBITORY ACTIVITY AND COMPOSITION CONTAINING THE SAME | VEDAN INTERNATIONAL HOLDINGS LTD (KY) | 2026-01-01 | — | — | US | disclosed |
| US-12365706-B2 | Macrocyclic peptides as potent inhibitors of K-RAS G12D mutant | MERCK SHARP & DOHME LLC (US) | 2025-07-22 | — | — | US | disclosed |
| CN-116970080-B | Anti-human MFAP5 monoclonal antibody and preparation method thereof, polynucleotide molecule, expression vector and host cell | 优睿赛思(武汉)生物科技有限公司 | 2024-08-13 | — | — | CN | disclosed |
| US-20230083431-A1 | MACROCYCLIC PEPTIDES AS POTENT INHIBITORS OF K-RAS G12D MUTANT | MERCK SHARP & DOHME LLC (US) | 2023-03-16 | — | — | US | disclosed |
| US-20230046728-A1 | TECHNOLOGIES USEFUL FOR ASSESSING PERMEABILITY | PARABILIS MEDICINES, INC. | 2023-02-16 | — | — | US | disclosed |
| EP-4076493-A1 | MACROCYCLIC PEPTIDES AS POTENT INHIBITORS OF K-RAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2022-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12365706-B2 | Macrocyclic peptides as potent inhibitors of K-RAS G12D mutant | KRAS, NRAS, HRAS | LTA4H 4262/4885MMP2 650/4885MMP7 1196/4885 |
| US-20230046728-A1 | TECHNOLOGIES USEFUL FOR ASSESSING PERMEABILITY | SLC47A2, EPCAM, SLC47A1 | LTA4H 529/4885MMP2 940/4885MMP7 641/4885 |
| US-20230083431-A1 | MACROCYCLIC PEPTIDES AS POTENT INHIBITORS OF K-RAS G12D MUTANT | KRAS, NRAS, HRAS | LTA4H 4262/4885MMP2 650/4885MMP7 1196/4885 |
| US-20260000728-A1 | PEPTIDE HAVING ACE INHIBITORY ACTIVITY AND COMPOSITION CONTAINING THE SAME | ACE, AGT, ACE2 | LTA4H 585/4885MMP2 201/4885MMP7 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.